Aap Pharma Technologies India Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 24-06-2024
- Paid Up Capital ₹ 0.55 Cr
as on 24-06-2024
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 50.09%
(FY 2020)
- Profit 21.23%
(FY 2020)
- Ebitda 53.37%
(FY 2020)
- Net Worth 31.52%
(FY 2020)
- Total Assets 26.15%
(FY 2020)
About Aap Pharma Technologies India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 0.55 Cr, as per Ministry of Corporate Affairs (MCA) records.
Sheela Jyothi and Sreenivasulu Guntha serve as directors at the Company.
- CIN/LLPIN
U24233TG2008PTC062352
- Company No.
062352
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
26 Dec 2008
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Aap Pharma Technologies India Private Limited offer?
Aap Pharma Technologies India Private Limited offers a wide range of products and services, including Pharma & Bioanalytical Services, Pharmaceutical Services.
Who are the key members and board of directors at Aap Pharma Technologies India?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sheela Jyothi  | Director | 25-Feb-2010 | Current |
| Sreenivasulu Guntha | Director | 26-Dec-2008 | Current |
Financial Performance and Corporate Structure Insights of Aap Pharma Technologies India.
Aap Pharma Technologies India Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 50.09% increase. The company also saw a substantial improvement in profitability, with a 21.23% increase in profit. The company's net worth Soared by an impressive increase of 31.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Aap Pharma Technologies India?
In 2020, Aap Pharma Technologies India had a promoter holding of 43.03% and a public holding of 56.97%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
4 years 3 months Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Aap Pharma Technologies India?
Aap Pharma Technologies India has a workforce of 76 employees as of Apr 07, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
As of Nov 08, 2013, Aap Pharma Technologies India has raised a total of ₹ 1.04 Cr, with the most recent deal valued at ₹ 5 M. Access detailed insights into the company’s deals, including security allotments, mergers, acquisitions, and strategic partnerships that have shaped its growth.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
